Blueprint Medicines CORP Form 4 insider transactions
A Blueprint Medicines director, Jeffrey W. Albers, exercised stock options and sold shares on January 21, 2025, under a pre-arranged trading plan.
A Blueprint Medicines director, Jeffrey W. Albers, exercised stock options and sold shares on January 13, 2025, according to a recent SEC filing.
Ariel Hurley, Principal Accounting Officer at Blueprint Medicines, exercised stock options and sold shares on January 13, 2025, according to a recent SEC filing.
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp on December 19, 2024, according to a Form 4 filing with the SEC.
Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold shares of common stock on December 18, 2024, under a pre-arranged trading plan.
Ariel Hurley, Principal Accounting Officer at Blueprint Medicines, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.
Blueprint Medicines CEO Kate Haviland sold a total of 2,353 shares of common stock on November 29, 2024, under a pre-arranged 10b5-1 trading plan.
Christina Rossi, Chief Operating Officer of Blueprint Medicines, sold 2,274 shares of common stock at an average price of $95.10, as part of a pre-arranged trading plan.
Director Lonnel Coats of Blueprint Medicines Corp. executed multiple stock sales and option exercises on November 20th and 21st, 2024, under a pre-arranged 10b5-1 trading plan.
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp. on November 7, 2024, according to a Form 4 filing.
Fouad Namouni, President of R&D at Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp. on September 9, 2024, according to a Form 4 filing with the SEC.
Michael Landsittel, CFO of Blueprint Medicines Corp, sold 4,409 shares of common stock on August 15, 2024, at a weighted average price of $95.23 per share.
Philina Lee, Chief Commercial Officer of Blueprint Medicines, executed stock options and sold shares on August 5, 2024, according to a Form 4 filing with the SEC.
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, acquired 7,500 shares of common stock on July 1, 2024, through a grant of restricted stock units.
Christina Rossi, Chief Operating Officer of Blueprint Medicines, reports acquiring 9,625 shares of common stock on July 1, 2024, through a grant of restricted stock units.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, exercised stock options and sold shares of common stock on July 3rd and 5th, 2024, under a pre-arranged trading plan.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, exercised stock options and sold shares on June 28, 2024, according to a Form 4 filing with the SEC.
Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines, exercised stock options and sold shares of common stock on June 21, 2024, according to a Form 4 filing with the SEC.
Director Jeffrey W. Albers receives restricted stock units and stock options from Blueprint Medicines Corp.
Director Daniella Beckman reports acquisition of restricted stock units and stock options in Blueprint Medicines Corp.
Director Lonnel Coats received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.
Director John Tsai reports acquisition of restricted stock units and stock options in Blueprint Medicines Corp.
Director Lynn Seely received stock and option grants from Blueprint Medicines Corp on June 12, 2024.
Director Nicholas Lydon received restricted stock units and stock options from Blueprint Medicines Corp.
Director Mark Alan Goldberg received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.
Director Alexis Borisy received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.
Director Habib J. Dable reports acquisition of restricted stock units and stock options in Blueprint Medicines Corp.
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, sold 4,000 shares of common stock on June 5, 2024, at a weighted average price of $105.13 per share.
L. Becker Hewes, Chief Medical Officer of Blueprint Medicines, sold 2,424 shares of common stock at $104.91 per share on June 4, 2024, under a pre-arranged trading plan.